Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Hansa Biopharma interim report Jan-Sept 2021

Hansa on track to achieve key 2021 objectives: · Agreements on funding obtained in three countries; HTA submissions in ten countries; and Marketing Authorization Applications filed in Switzerland and Israel · Growing number of patient candidates identified as leading transplantation centers get clinically ready to transplant this underserved population · Enrollment in AMR and GBS programs accelerated by initiation of additional centers; On track for completion according to previous guidance  · Dialogue with FDA on regulatory path in anti-GBM expected to be concluded later this

Alimak Group: Interim report January – September 2021

Continued profit improvements · Continued strong order intake in Construction and Industrial · Strong service growth, up 26% in the quarter · New Heights Programme delivering margin improvements in line with plan · Still challenges in Wind and BMU (Building Maintenance Units)Third quarter · Order intake decreased by 2% to MSEK 872 (888) with an organic decrease of 3% · Strong organic order intake growth in Construction, up 14%, and in Industrial, up 19% · Revenue decreased by 1% to MSEK 902 (916) with an organic decrease of 5% · EBITA increased to MSEK 119 (67),

Nexam Chemical Holding AB (publ) Interim Report 1 January – 30 September 2021

Growth with 22 percent in the quarterThird quarter at a glance Significant events: · Continued growth, +22% compared to the corresponding quarter in 2020. · Both Performance Chemical, + 22%, and Performance Masterbatch, + 23%, are growing compared to the corresponding quarter in 2020. · Important customer orders received to India for PET foam, worth SEK 10 million for the remainder of 2021 and to Russia in polyolefin. The latter took place after the end of the quarter. · Strong order intake during the quarter, indicates a strong finish of 2021. · During the quarter,

Interim Report January–September 2021

Third quarter · Order intake amounted to SEK 1,242 (739) million, up 68 percent · Net sales decreased 8 percent to SEK 986 (1,068) million. Based on constant exchange rates, net sales decreased 9 percent · EBIT declined to SEK 106 (348) million and EBIT margin was 11 (33) percent  · Earnings per share were SEK 0.82 (2.71) January–September · Order intake amounted to SEK 3,272 (2,822) million, up 16 percent · Net sales increased 16 percent to SEK 3,341 (2,889) million. Based on constant exchange rates, the increase was 21 percent · EBIT rose to SEK 845 (684) million

EQT Private Equity and Vitruvian Partners announce significant investment in CFC

EQT Private Equity has agreed to make a significant investment together with Vitruvian Partners in CFC, a leading technology-driven global insurance businessCFC is a specialist insurance provider, pioneer in emerging risk and market leader in cyber, serving more than 100,000 businesses in over 90 countries. EQT Private Equity and Vitruvian Partners will support CFC’s investments in innovative and market-leading technology and in continuing to deliver best-in-class products and services to its customersEQT is pleased to announce that the EQT IX fund (“EQT Private Equity”) has agreed to

Trading in Isofol’s shares commences today on Nasdaq Stockholm

GOTHENBURG, Sweden, October 21, 2021 - Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), (”Isofol” or the ”Company”), announced today that the Company’s shares are admitted to trading on Nasdaq Stockholm.The shares of the Company will be traded with unchanged ticker ISOFOL and ISIN-code (SE0009581051). No new shares will be issued in connection with the shares being admitted to trading on Nasdaq Stockholm and the Company’s shareholders do not need to take any actions in connection with the listing. The prospectus prepared by the Company in connection with the listing was approved and

Commercial International Bank of Egypt Partners with Truecaller

CIB’s partnership with Truecaller for Business is in line with CIB’s commitment to providing secure high-quality services to its customers and protecting their data. Cairo, Egypt — Commercial International Bank (CIB), the largest private sector bank in Egypt, announced a new partnership with Truecaller for Business, a global platform for verifying contacts and blocking unwanted communication, to bring trust and safety to customer communication.Truecaller, the leading global platform for verifying contacts and blocking unwanted communication, is pleased to announce a new commercial

Interim report, January–September 2021

New orders drive increased growth rateJanuary–September 2021 · Revenue amounted to TSEK 118,169 (126,844) · Operating profit amounted to TSEK -84,353 (-28,958) · Profit after tax amounted to TSEK -62,131 (-48,366). The result includes currency conversions and financial transaction costs of TSEK 22,475 (-22,397) · Earnings per share amounted to SEK -1.34 (-1.19) July–September 2021 · Revenue increased to TSEK 47,823 (32,285) · Operating profit amounted to TSEK -22,785 (-17,000) · Profit after tax amounted to TSEK -12,339 (-30,180). The result includes currency

Interim Report for the period July – September 2021

Eisai initiates Biologics License Application of lecanemab in the US earlier than expected  Events during the third quarter 2021 ·Eisai has initiated a rolling submission for the US FDA Biologics License Application of lecanemab, under the accelerated approval pathway. The objective is for lecanemab to be approved for the treatment of patients with early Alzheimer’s disease. ·Data from the Phase 2b open-label extension study of lecanemab presented at the Alzheimer’s Association International Conference provided further support for the clinical effects of the drug

ContextVision - Aiming to build the company’s first modern pathology lab

STOCKHOLM – October 21, 2021 – ContextVision, a medical technology software company specializing in image processing and decision support tools within digital pathology, has decided to build its first fully digital pathology laboratory – thus confirming its strong dedication to advancing digitalization within pathology, for the best of both patients and the medical profession. Sales in the third quarter reached 26.0 MSEK (22.0), a 7% increase compared with the previous quarter, and an increase of 18% versus last year's corresponding quarter. EBITDA ended at 5.7 MSEK and the cash position

Interim Report, January-September 2021

Third quarter · Net sales amounted to MSEK 92.8 (75.6), rendering a net sales growth of 23 % (11 %) · Recurring revenue amounted to MSEK 64.7 (48.5) · The quarter was impacted by one-off items affecting comparison, amounting to MSEK -0.0 (0.0). Comparison attributable to acquisitions · Adjusted EBITA amounted to MSEK 25.5 (24.7) which corresponds to an adjusted EBITA margin of 27 % (33 %) · Net income amounted to MSEK 11.1 (15.0) · Earnings per share SEK 0.83 (1.13) and diluted SEK 0.83 (1.13)   First nine months · Net sales MSEK 290.2 (245.6), rendering a

Interim Report January – September 2021

With the new ownership structure that came into force in September, we will accelerate our development of a larger self-management portfolio. During Q3, we started production of just over 600 residential units, of which around 190 relate to sales of a project in Enköping. We took another step forward in our sustainability work and together with other property companies started Sustainable Stockholm 2030 (HS30).January–September 2021 · Net sales amounted to SEK 552 m (1,785). · The operating profit was SEK 64 m (+627). Changes in the value of investment properties contributed

Interim Report for Duni AB (publ) January 1–September 30, 2021

Strong quarterly results as markets open upJuly 1–September 30 · Net sales amounted to SEK 1,453 m (1,251), corresponding to a 16.2% increase in sales. Adjusted for exchange rate movements, net sales increased by 19.0%. · Earnings per share after dilution amounted to SEK 2.16 (1.02). · Strong recovery in sales for the Duni business area and continued high growth rate for the BioPak business area. · High efficiency in factories and strong operational leverage on indirect costs boost income. · Prices of raw materials, energy and sea freight continued to accelerate during the

Alligator Announces First Patient Dosed in Phase II Clinical Trial with Shanghai Henlius Biotech, Inc. & AbClon, Inc.

Lund, Sweden, October 20, 2021 – Alligator Bioscience AB (“Alligator” or the “Company”) today announced that the Company was notified that the first patient has been dosed in its Phase II clinical trial collaboration with Shanghai Henlius Biotech, Inc. and AbClon, Inc. Alligator out-licensed AC101 to AbClon, Inc. in October 2016. Abclon, Inc. subsequently sub-licensed AC101 in China for clinical development by Shanghai Henlius Biotech Inc. (November 7, 2018 press release 

DNB Bank ASA - cash dividend for 2020 - key information

The Board of Directors of DNB Bank ASA has decided to distribute a cash dividend of NOK 9 per share for the accounting year of 2020, in accordance with the authorisation granted by the ordinary general meeting held on 27 April 2021. Dividend amount: 9.00 per share Declared currency: Norwegian krone (NOK) Last day including right: 27 October 2021 Ex-date: 28 October 2021 Record date (shareholder registration date): 29 October 2021 Payment date: 5 November 2021 Date of approval: 20 October 2021 This information is published in accordance with the requirements in Oslo

Aqilion presents new preclinical data in the Alnitak program showing unique results in rheumatoid arthritis disease model

AQILION AB (publ) is presenting preclinical data in the Alnitak program for the first time at the conference BIO-Europe 2021. The Alnitak program focuses on inhibition of the TAK1 target protein. By directly inhibiting TAK1, the biology underlying the inflammatory processes that arise in various autoimmune diseases is affected. Aqilion is now presenting positive efficacy data from studies in a rheumatoid arthritis disease model with one of its TAK1 inhibitors. This is the first time that a drug-like substance that specifically inhibits TAK1 demonstrates favorable data in a disease model,

ADDvise signs Letter of Intent to acquire Poly Pharmaceuticals, Inc.

ADDvise Group AB (publ) has signed a Letter of Intent with the shareholders of Poly Pharmaceuticals, Inc. (”Poly Pharma”) regarding an acquisition of 100 percent of the shares in Poly Pharma. Poly Pharma is an American pharmaceutical company specializing in the development, production and marketing of over-the-counter generic pharmaceuticals for treatment of coughs, colds, allergies, sinusitis, urological health and pain relief. Sales are mainly to pharmacies and general practitioners. The company markets and sells 20 proprietary pharmaceuticals in the U.S. market, including Folite,

Interim report January-September 2021

Collector AB publishes the interim report for the period January-September 2021.THIRD QUARTER OF 2021 (COMPARED TO THE THIRD QUARTER OF 2020) · The loan portfolio amounted to SEK 35,624 million (30,146) · Total income amounted to SEK 658 million (525) · The C/I ratio amounted to 27.9% (38.0) · Profit before credit losses amounted to SEK 474 million (326) · The credit loss level amounted to 2.6% (2.8) · Operating profit amounted to SEK 244 million (117) · Net profit amounted to SEK 190 million (89) and earnings per share amounted to SEK 0.93 (0.43) · The CET1 ratio

Kappahl combines growth strategy with reduced climate impact

Kappahl’s vision of a sustainable future is one in which people’s clothing needs are in balance with their environmental impact. Kappahl has developed a climate strategy that is commercially viable and anchored within the fashion chain’s ambitious growth plan. It is also environmentally realistic, as it is in line with The Paris agreement.      ‘We needed to ensure that our future ambitions aligned with our climate goals. For that reason we have drawn up a climate strategy where our calculations are based on us meeting our climate goals as well as our growth targets,’ Kappahl’s CEO

High level of activity after the reopening

21 October 2021 DNB has delivered its best ever third quarter with a profit of NOK 6 883 million, which is an increase of NOK 1 337 million from the corresponding quarter last year, and of NOK 451 million from the second quarter of this year. Norwegian society has been completely reopened, there is an upturn in the economy, and unemployment has fallen to the same level as in February 2020. After a very good first half of the year, DNB is continuing to strengthen its financial position, and all parts of the bank are developing positively. “All important indicators are pointing in

Skanska divests part of Swedish logistics portfolio for SEK 1.1 billion, potential value SEK 2.1 billion in total

Skanska is divesting a portfolio of six logistics projects in Sweden to Barings. In a first stage, the divestment of two projects, at a total value of SEK 1.1 billion, will be recorded by Commercial Development Nordic in the fourth quarter 2021. Transfer of the properties will take place in connection with completion in 2022 and 2023.The two properties in the first phase of the portfolio deal include a project in Helsingborg of 44,000 square meters, which was leased to Greenfood in the second quarter 2021, and another project in Helsingborg. In total, the portfolio comprises approximately

SpareBank 1 SR-Bank ASA: SpareBank 1 Gruppen – result 3[rd] quarter and the first three quarters of 2021.

SpareBank 1 SR-Bank ASA has an ownership share of 19.5 % in SpareBank 1 Gruppen AS. SpareBank 1 SR-Bank’s share of SpareBank 1 Gruppen's profit after tax in the 3[rd] quarter was NOK 82.9 million. SpareBank 1 SR-Bank’s share of SpareBank 1 Gruppen's profit after tax as of 30 September 2021 was NOK 297.8 million. The SpareBank 1 Gruppen’s profit before tax as of 30 September 2021 was NOK 2,816 million. Profit after tax was NOK 2,170 million. The controlling interest’s share of the profit in the 3[rd] quarter and as of 30 September 2021 was resp. NOK 425 and NOK 1.527 million. The SpareBank 1

Nyfosa Interim report January–September 2021

JANUARY–SEPTEMBER 2021 · Income amounted to MSEK 1,788 (1,477), up 21 percent. · Profit from property management amounted to MSEK 1,372 (969), up 42 percent. · Profit from property management excluding changes in value and tax in joint ventures amounted to MSEK 957 (870), up 10 percent. · Distributable cash flow per share amounted to SEK 5.35 (5.66), down 5 percent. · Profit after tax amounted to MSEK 2,051 (1,728). · Profit after tax per share was SEK 10.94 (9.55). JULY–SEPTEMBER 2021 · Income amounted to MSEK 634 (554), up 14 percent. · Profit from property

Epiroc interim report Q3 2021

· Orders received increased 31% to MSEK 12 245 (9 373), organic increase of 24%. Acquisitions contributed with 7%. · Revenues increased 14% to MSEK 9 966 (8 724), organic increase of 11%. · Operating profit increased 29% to MSEK 2 352 (1 820), including items affecting comparability of MSEK 21 (-76).* · Operating margin improved to 23.6% (20.9) and the adjusted operating margin improved to 23.4% (21.7). · Basic earnings per share were SEK 1.60 (1.10). · Operating cash flow was MSEK 1 613 (1 355). · Agreement made to acquire FVT Research, a specialist in mining vehicle

There are no items matching the current filter
There are no more items matching the current filter
Back to top